ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia (2024)
Silva, Jean Carlos Lipreri da ; Silva, Juan Luiz Coelho da ; Vicari, Hugo Passos ; Lima, Keli Cristina de ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Hematology, Transfusion and Cell Therapy. Unidades: FM, FMRP, ICB
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, MEDULA ÓSSEA, CÉLULAS SANGUÍNEAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Jean Carlos Lipreri da et al. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2023.06.004. Acesso em: 31 maio 2024. , 2024
APA
Silva, J. C. L. da, Silva, J. L. C. da, Vicari, H. P., Lima, K. C. de, Rego, E. M., Traina, F., & Machado Neto, J. A. (2024). ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina, Universidade de São Paulo. doi:https://doi.org/10.1016/j.htct.2023.06.004
NLM
Silva JCL da, Silva JLC da, Vicari HP, Lima KC de, Rego EM, Traina F, Machado Neto JA. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2024 ; 46( 1): 105-106.[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.htct.2023.06.004
Vancouver
Silva JCL da, Silva JLC da, Vicari HP, Lima KC de, Rego EM, Traina F, Machado Neto JA. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2024 ; 46( 1): 105-106.[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.htct.2023.06.004
Artigo de periodico
Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia (2023)
Lima, Keli Cristina de ; Carvalho, Maria Fernanda Lopes ; Martins, Diego Antonio Pereira ; Nascimento, Mariane Cristina do ; Nogueira, Frederico Lisboa ; Medeiros, Rita de Cássia Cavaglieri ; Schuringa, Jan Jacob ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho
Source: Blood. Conference titles: 65th ASH Annual Meeting Abstracts. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, HEMATOLOGIA, LEUCEMIA MIELOIDE AGUDA, QUIMIOTERAPIA COMBINADA, CÉLULAS CULTIVADAS DE TUMOR, PROLIFERAÇÃO CELULAR, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTINEOPLÁSICOS, PROTEÍNAS, CÉLULAS MIELOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia. Blood, v. 142, n. Supl. 1, p. 5774, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-189998. Acesso em: 31 maio 2024.
APA
Lima, K. C. de, Carvalho, M. F. L., Martins, D. A. P., Nascimento, M. C. do, Nogueira, F. L., Medeiros, R. de C. C., et al. (2023). Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia. Blood, 142( Supl. 1), 5774. doi:10.1182/blood-2023-189998
NLM
Lima KC de, Carvalho MFL, Martins DAP, Nascimento MC do, Nogueira FL, Medeiros R de CC, Schuringa JJ, Rego EM, Machado Neto JA. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia [Internet]. Blood. 2023 ; 142( Supl. 1): 5774.[citado 2024 maio 31 ] Available from: https://doi.org/10.1182/blood-2023-189998
Vancouver
Lima KC de, Carvalho MFL, Martins DAP, Nascimento MC do, Nogueira FL, Medeiros R de CC, Schuringa JJ, Rego EM, Machado Neto JA. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia [Internet]. Blood. 2023 ; 142( Supl. 1): 5774.[citado 2024 maio 31 ] Available from: https://doi.org/10.1182/blood-2023-189998
Artigo de periodico
Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models (2023)
Nascimento, Mariane Cristina do ; Martins, Diego Antonio Pereira ; Alcântara, Guilherme Augusto Sousa; Lima, Keli Cristina de ; Vicari, Hugo Passos ; Huls, Gerwin A. ; Schuringa, Jan Jacob ; Rego, Eduardo Magalhães ; Ferreira, Marcelo José Pena ; Costa-Lotufo, Leticia Veras ; Machado Neto, João Agostinho
Source: Blood. Conference titles: 65th ASH Annual Meeting Abstracts. Unidades: IB, FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, HEMATOLOGIA, QUIMIOTERAPIA COMBINADA, CÉLULAS CULTIVADAS DE TUMOR, PROLIFERAÇÃO CELULAR, NEOPLASIAS POR TIPO HISTOLÓGICO, APOPTOSE, DANO AO DNA, MITOCÔNDRIAS, PROTEÔMICA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NASCIMENTO, Mariane Cristina do et al. Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models. Blood, v. 142, n. res. 604, p. 5751, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-189814. Acesso em: 31 maio 2024.
APA
Nascimento, M. C. do, Martins, D. A. P., Alcântara, G. A. S., Lima, K. C. de, Vicari, H. P., Huls, G. A., et al. (2023). Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models. Blood, 142( res. 604), 5751. doi:10.1182/blood-2023-189814
NLM
Nascimento MC do, Martins DAP, Alcântara GAS, Lima KC de, Vicari HP, Huls GA, Schuringa JJ, Rego EM, Ferreira MJP, Costa-Lotufo LV, Machado Neto JA. Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models [Internet]. Blood. 2023 ; 142( res. 604): 5751.[citado 2024 maio 31 ] Available from: https://doi.org/10.1182/blood-2023-189814
Vancouver
Nascimento MC do, Martins DAP, Alcântara GAS, Lima KC de, Vicari HP, Huls GA, Schuringa JJ, Rego EM, Ferreira MJP, Costa-Lotufo LV, Machado Neto JA. Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models [Internet]. Blood. 2023 ; 142( res. 604): 5751.[citado 2024 maio 31 ] Available from: https://doi.org/10.1182/blood-2023-189814
Artigo de periodico
Intracellular peptides in SARS-CoV-2-infected patients (2023)
Martucci, Luiz Felipe ; Eichler, Rosangela Aparecida dos Santos ; Silva, Renée de Nazaré Oliveira da ; Costa, Tiago Januário da ; Tostes, Rita de Cássia Aleixo ; Bussato Filho, Geraldo; Seelander, Marilia Cerqueira Leite ; Duarte, Alberto J. S.; Souza, Heraldo Possolo de ; Ferro, Emer S.
Source: iScience. Unidades: ICB, FM, FMRP
Subjects: FARMACOLOGIA, CORONAVIRUS, COVID-19, ESPECTROMETRIA DE MASSAS, PEPTÍDEOS, PLASMA, ISÓTOPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTUCCI, Luiz Felipe et al. Intracellular peptides in SARS-CoV-2-infected patients. iScience, v. 26, n. 9, p. 17 , 2023Tradução . . Disponível em: https://doi.org/10.1016/j.isci.2023.107542. Acesso em: 31 maio 2024.
APA
Martucci, L. F., Eichler, R. A. dos S., Silva, R. de N. O. da, Costa, T. J. da, Tostes, R. de C. A., Bussato Filho, G., et al. (2023). Intracellular peptides in SARS-CoV-2-infected patients. iScience, 26( 9), 17 . doi:10.1016/j.isci.2023.107542
NLM
Martucci LF, Eichler RA dos S, Silva R de NO da, Costa TJ da, Tostes R de CA, Bussato Filho G, Seelander MCL, Duarte AJS, Souza HP de, Ferro ES. Intracellular peptides in SARS-CoV-2-infected patients [Internet]. iScience. 2023 ; 26( 9): 17 .[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.isci.2023.107542
Vancouver
Martucci LF, Eichler RA dos S, Silva R de NO da, Costa TJ da, Tostes R de CA, Bussato Filho G, Seelander MCL, Duarte AJS, Souza HP de, Ferro ES. Intracellular peptides in SARS-CoV-2-infected patients [Internet]. iScience. 2023 ; 26( 9): 17 .[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.isci.2023.107542
Artigo de periodico
Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia (2023)
Lima, Keli Cristina de ; Carvalho, Maria Fernanda Lopes ; Pereira-Martins, Diego Antonio ; Nogueira, Frederico Lisboa ; Miranda, Lívia Bassani Lins de ; Mariane Cristina do Nascimento ; Cavaglieri, Rita de Cássia ; Schuringa, Jan Jacob ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho
Source: International Journal of Molecular Sciences. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTINEOPLÁSICOS, APOPTOSE, PROTEÍNAS PROTO-ONCOGÊNICAS, COMPOSTOS HETEROCÍCLICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia. International Journal of Molecular Sciences, v. 24, n. 23, p. 12 , 2023Tradução . . Disponível em: https://doi.org/10.3390/ijms242316899. Acesso em: 31 maio 2024.
APA
Lima, K. C. de, Carvalho, M. F. L., Pereira-Martins, D. A., Nogueira, F. L., Miranda, L. B. L. de, Mariane Cristina do Nascimento,, et al. (2023). Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 24( 23), 12 . doi:https://doi.org/10.3390/ijms242316899
NLM
Lima KC de, Carvalho MFL, Pereira-Martins DA, Nogueira FL, Miranda LBL de, Mariane Cristina do Nascimento, Cavaglieri R de C, Schuringa JJ, Rego EM, Machado Neto JA. Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia [Internet]. International Journal of Molecular Sciences. 2023 ; 24( 23): 12 .[citado 2024 maio 31 ] Available from: https://doi.org/10.3390/ijms242316899
Vancouver
Lima KC de, Carvalho MFL, Pereira-Martins DA, Nogueira FL, Miranda LBL de, Mariane Cristina do Nascimento, Cavaglieri R de C, Schuringa JJ, Rego EM, Machado Neto JA. Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia [Internet]. International Journal of Molecular Sciences. 2023 ; 24( 23): 12 .[citado 2024 maio 31 ] Available from: https://doi.org/10.3390/ijms242316899
Artigo de periodico
Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia (2022)
Lima, Keli ; Pereira-Martins Diego A. ; Miranda, Lívia Bassani Lins de ; Coelho-Silva, Juan L. ; Leandro, Giovana da Silva ; Isabel Weinhäuser ; Cavaglieri, Rita de Cássia ; Silva, Wellington F.; Leal, Aline Medeiros; Lange, Ana Paula Alencar de Lima; Velloso, Elvira Deolinda Rodrigues Pereira ; Griessinger, Emmanuel ; Hilberink, Jacobien R. ; Huls, Gerwin A. ; Schuringa, Jan Jacob ; Rego, Eduardo M. ; Machado Neto, João Agostinho
Source: Blood. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, AMINOÁCIDOS, PROTEÍNAS QUINASES, DANO AO DNA, MITOCÔNDRIAS, HOMEOSTASE, LISOSSOMOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia. Blood, v. 140, p. 5965–5966, 2022Tradução . . Disponível em: https://doi.org/10.1182/blood-2022-165172. Acesso em: 31 maio 2024.
APA
Lima, K., Pereira-Martins Diego A.,, Miranda, L. B. L. de, Coelho-Silva, J. L., Leandro, G. da S., Isabel Weinhäuser,, et al. (2022). Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia. Blood, 140, 5965–5966. doi:10.1182/blood-2022-165172
NLM
Lima K, Pereira-Martins Diego A., Miranda LBL de, Coelho-Silva JL, Leandro G da S, Isabel Weinhäuser, Cavaglieri R de C, Silva WF, Leal AM, Lange APA de L, Velloso EDRP, Griessinger E, Hilberink JR, Huls GA, Schuringa JJ, Rego EM, Machado Neto JA. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia [Internet]. Blood. 2022 ; 140 5965–5966.[citado 2024 maio 31 ] Available from: https://doi.org/10.1182/blood-2022-165172
Vancouver
Lima K, Pereira-Martins Diego A., Miranda LBL de, Coelho-Silva JL, Leandro G da S, Isabel Weinhäuser, Cavaglieri R de C, Silva WF, Leal AM, Lange APA de L, Velloso EDRP, Griessinger E, Hilberink JR, Huls GA, Schuringa JJ, Rego EM, Machado Neto JA. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia [Internet]. Blood. 2022 ; 140 5965–5966.[citado 2024 maio 31 ] Available from: https://doi.org/10.1182/blood-2022-165172
Artigo de periodico
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy (2022)
Lima, Keli Cristina de ; Martins, Diego Antonio Pereira ; Miranda, Lívia Bassani Lins De ; Silva, Juan Luiz Coelho ; Leandro, Giovana da Silva ; Weinhäuser, Isabel ; Cavaglieri, Rita de Cássia; Leal, Aline de Medeiros; Silva, Wellington Fernandes da; Lange, Ana Paula Alencar de Lima; Velloso, Elvira Deolinda Rodrigues Pereira ; Rego, Eduardo Magalhães ; Griessinger, Emmanuel ; Hilberink, Jacobien R. ; Ammatuna, Emanuele ; Huls, Gerwin ; Schuringa, Jan Jacob ; Machado Neto, João Agostinho
Source: Blood Cancer Journal. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, HOMEOSTASE, APOPTOSE, MITOCÔNDRIAS, ESPECTROMETRIA DE MASSAS, CROMATOGRAFIA LÍQUIDA, CÉLULAS-TRONCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy. Blood Cancer Journal, v. 12, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41408-022-00747-w. Acesso em: 31 maio 2024.
APA
Lima, K. C. de, Martins, D. A. P., Miranda, L. B. L. D., Silva, J. L. C., Leandro, G. da S., Weinhäuser, I., et al. (2022). The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy. Blood Cancer Journal, 12, 1-11. doi:10.1038/s41408-022-00747-w
NLM
Lima KC de, Martins DAP, Miranda LBLD, Silva JLC, Leandro G da S, Weinhäuser I, Cavaglieri R de C, Leal A de M, Silva WF da, Lange APA de L, Velloso EDRP, Rego EM, Griessinger E, Hilberink JR, Ammatuna E, Huls G, Schuringa JJ, Machado Neto JA. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy [Internet]. Blood Cancer Journal. 2022 ; 12 1-11.[citado 2024 maio 31 ] Available from: https://doi.org/10.1038/s41408-022-00747-w
Vancouver
Lima KC de, Martins DAP, Miranda LBLD, Silva JLC, Leandro G da S, Weinhäuser I, Cavaglieri R de C, Leal A de M, Silva WF da, Lange APA de L, Velloso EDRP, Rego EM, Griessinger E, Hilberink JR, Ammatuna E, Huls G, Schuringa JJ, Machado Neto JA. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy [Internet]. Blood Cancer Journal. 2022 ; 12 1-11.[citado 2024 maio 31 ] Available from: https://doi.org/10.1038/s41408-022-00747-w
Artigo de periodico
Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells (2022)
Fernandes, Jaqueline Cristina; Fenerich, Bruna Alves ; Silva, Antônio Bruno Alves; Fonseca, Natasha Peixoto ; Silva, Juan Luiz Coelho ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Pontes, Lorena Lôbo Figueiredo ; Machado Neto, João Agostinho ; Traina, Fabiola
Source: Toxicology in Vitro. Unidades: FM, FMRP, ICB
Subjects: FARMACOLOGIA, ANTINEOPLÁSICOS, INIBIDORES QUÍMICOS, MEDULA ÓSSEA, CÉLULAS-TRONCO, PROLIFERAÇÃO CELULAR, APOPTOSE, MUTAÇÃO, CÉLULAS MIELOIDES, FATORES DE CRESCIMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDES, Jaqueline Cristina et al. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, v. 83, p. 1-7, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.tiv.2022.105384. Acesso em: 31 maio 2024.
APA
Fernandes, J. C., Fenerich, B. A., Silva, A. B. A., Fonseca, N. P., Silva, J. L. C., Scheucher, P. S., et al. (2022). Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, 83, 1-7. doi:10.1016/j.tiv.2022.105384
NLM
Fernandes JC, Fenerich BA, Silva ABA, Fonseca NP, Silva JLC, Scheucher PS, Rego EM, Pontes LLF, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells [Internet]. Toxicology in Vitro. 2022 ; 83 1-7.[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.tiv.2022.105384
Vancouver
Fernandes JC, Fenerich BA, Silva ABA, Fonseca NP, Silva JLC, Scheucher PS, Rego EM, Pontes LLF, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells [Internet]. Toxicology in Vitro. 2022 ; 83 1-7.[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.tiv.2022.105384
Artigo de periodico-carta/editorial
Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax (2022)
Lima, Keli Cristina de ; Vicari, Hugo Passos ; Carlos, Jorge Antonio Elias Godoy; Silva, Jean Carlos Lipreri da ; Pontes, Lorena Lobo de Figueiredo ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho
Source: Hematology, Transfusion and Cell Therapy. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, APOPTOSE, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2021.01.004. Acesso em: 31 maio 2024. , 2022
APA
Lima, K. C. de, Vicari, H. P., Carlos, J. A. E. G., Silva, J. C. L. da, Pontes, L. L. de F., Rego, E. M., & Machado Neto, J. A. (2022). Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.htct.2021.01.004
NLM
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004
Vancouver
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004
Artigo de periodico
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model (2022)
Silva, Antônio Bruno Alves; Fenerich, Bruna Alves ; Fonseca, Natasha Peixoto ; Fernandes, Jaqueline Cristina; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Bianco, Thiago Mantello ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Chahud, Fernando ; Machado Neto, João Agostinho ; Pontes, Lorena Lôbo de Figueiredo ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, ANTIDIABÉTICOS (HIPOGLICEMIANTES), HEMATOPOESE, CÉLULAS SANGUÍNEAS, CÉLULAS-TRONCO, DOENÇAS HEMATOLÓGICAS, POLICITEMIA, PLAQUETAS SANGUÍNEAS, ANTINEOPLÁSICOS, CAMUNDONGOS, MODELOS ANIMAIS DE DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Antônio Bruno Alves et al. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10637-022-01212-y. Acesso em: 31 maio 2024.
APA
Silva, A. B. A., Fenerich, B. A., Fonseca, N. P., Fernandes, J. C., Silva, J. L. C. da, Martins, D. A. P., et al. (2022). Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, 1-10. doi:10.1007/s10637-022-01212-y
NLM
Silva ABA, Fenerich BA, Fonseca NP, Fernandes JC, Silva JLC da, Martins DAP, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado Neto JA, Pontes LL de F, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s10637-022-01212-y
Vancouver
Silva ABA, Fenerich BA, Fonseca NP, Fernandes JC, Silva JLC da, Martins DAP, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado Neto JA, Pontes LL de F, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s10637-022-01212-y
Artigo de periodico
Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome (2021)
Silva, Juan Luiz Coelho ; Silveira, Douglas Rafaele Almeida ; Martins, Diego Antonio Pereira ; Rojas, Cesar A. O.; Araujo, Antonio R. Lucena ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho ; Bendit, Israel ; Rocha, Vanderson Geraldo ; Traina, Fabiola
Source: Scientific Reports. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, FARMACOGENÉTICA, EXPRESSÃO GÊNICA, CICLO CELULAR, MEDULA ÓSSEA, DOENÇAS SANGUÍNEAS E LINFÁTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Juan Luiz Coelho et al. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, v. 11, p. 11 , 2021Tradução . . Disponível em: https://doi.org/10.1038/s41598-020-80918-6. Acesso em: 31 maio 2024.
APA
Silva, J. L. C., Silveira, D. R. A., Martins, D. A. P., Rojas, C. A. O., Araujo, A. R. L., Rego, E. M., et al. (2021). Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, 11, 11 . doi:10.1038/s41598-020-80918-6
NLM
Silva JLC, Silveira DRA, Martins DAP, Rojas CAO, Araujo ARL, Rego EM, Machado Neto JA, Bendit I, Rocha VG, Traina F. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome [Internet]. Scientific Reports. 2021 ; 11 11 .[citado 2024 maio 31 ] Available from: https://doi.org/10.1038/s41598-020-80918-6
Vancouver
Silva JLC, Silveira DRA, Martins DAP, Rojas CAO, Araujo ARL, Rego EM, Machado Neto JA, Bendit I, Rocha VG, Traina F. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome [Internet]. Scientific Reports. 2021 ; 11 11 .[citado 2024 maio 31 ] Available from: https://doi.org/10.1038/s41598-020-80918-6
Artigo de periodico
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells (2021)
Vicari, Hugo Passos ; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Araujo, Antônio Roberto Lucena de ; Lima, Keli Cristina de ; Silva, Jean Carlos Lipreri da ; Scheucher, Priscila Santos ; Koury, Luisa C.; Melo, Raul A. de ; Bittencourt, Rosane; Pagnano, Katia ; Nunes, Elenaide ; Fagundes, Evandro Maranhão ; Kerbauy, Fabio; Pontes, Lorena Lobo de Figueiredo ; Lotufo, Leticia Veras Costa ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Investigational New Drugs. Unidades: FMRP, ICB, FM
Subjects: FARMACOLOGIA, CÉLULAS SANGUÍNEAS, CLONAGEM, LEUCEMIA MIELOIDE AGUDA, ONCOPROTEÍNAS, CÉLULAS MIELOIDES, CICLO CELULAR, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VICARI, Hugo Passos et al. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, p. 1-15, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-021-01197-0. Acesso em: 31 maio 2024.
APA
Vicari, H. P., Silva, J. L. C. da, Martins, D. A. P., Araujo, A. R. L. de, Lima, K. C. de, Silva, J. C. L. da, et al. (2021). STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 1-15. doi:10.1007/s10637-021-01197-0
NLM
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima KC de, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Lotufo LVC, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Vancouver
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima KC de, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Lotufo LVC, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Artigo de periodico
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021)
Ribeiro, Renata Scopim ; Machado Neto, João Agostinho ; Eide, Christopher A. ; Silva, Juan Luiz Coelho da ; Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Scheucher, Priscila Santos ; Stevens, Samantha L. Savage ; Campos, Paula de Melo; Saad, Sara T. Olalla ; Palma, Leonardo de Carvalho ; Pontes, Lorena Lobo de Figueiredo ; Simões, Belinda Pinto ; Rego, Eduardo Magalhães ; Tognon, Cristina E. ; Druker, Brian J. ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: ICB, FMRP, FM
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, v. 39, n. 3, p. 736-746, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-020-01028-8. Acesso em: 31 maio 2024.
APA
Ribeiro, R. S., Machado Neto, J. A., Eide, C. A., Silva, J. L. C. da, Fenerich, B. A., Fernandes, J. C., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 39( 3), 736-746. doi:10.1007/s10637-020-01028-8
NLM
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Vancouver
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Artigo de periodico
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells (2020)
Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Alves, Ana Paula Nunes Rodrigues; Silva, Juan Luiz Coelho da ; Ribeiro, Renata Scopim; Scheucher, Priscila Santos ; Eide, Christopher A.; Tognon, Cristina E.; Druker, Brian J. ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho ; Traina, Fabiola
Source: Signal Transduction and Targeted Therapy. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, TRANSDUÇÃO DE SINAL CELULAR, CÉLULAS CULTIVADAS DE TUMOR, ANTINEOPLÁSICOS, PROLIFERAÇÃO CELULAR, ERITROPOIETINA, APOPTOSE, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FENERICH, Bruna Alves et al. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, p. 10 , 2020Tradução . . Disponível em: https://doi.org/10.1038/s41392-019-0102-5. Acesso em: 31 maio 2024.
APA
Fenerich, B. A., Fernandes, J. C., Alves, A. P. N. R., Silva, J. L. C. da, Ribeiro, R. S., Scheucher, P. S., et al. (2020). NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, 10 . doi:10.1038/s41392-019-0102-5
NLM
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2024 maio 31 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Vancouver
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2024 maio 31 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Artigo de periodico
Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia (2009)
Andrade, Cláudia Roberta de; Leite, P. F.; Montezano, Augusto C.; Casolari, Débora Arcieri; Yogi, Alvaro; Passaglia, Rita de Cássia Aleixo Tostes; Haddad, Renato; Eberlin, Marcos Nogueira; Laurindo, Francisco Rafael Martins; Souza, Heraldo Possolo de; Corrêa, Fernando Morgan de Aguiar; Oliveira, Ana Maria de
Source: British Journal of Pharmacology. Unidades: FM, FMRP, FCFRP, ICB
Subjects: ARTÉRIAS CARÓTIDAS, ENDOTÉLIO, FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANDRADE, Cláudia Roberta de et al. Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia. British Journal of Pharmacology, v. 157, n. 4, p. 568-580, 2009Tradução . . Disponível em: https://doi.org/10.1111/j.1476-5381.2009.00165.x. Acesso em: 31 maio 2024.
APA
Andrade, C. R. de, Leite, P. F., Montezano, A. C., Casolari, D. A., Yogi, A., Passaglia, R. de C. A. T., et al. (2009). Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia. British Journal of Pharmacology, 157( 4), 568-580. doi:10.1111/j.1476-5381.2009.00165.x
NLM
Andrade CR de, Leite PF, Montezano AC, Casolari DA, Yogi A, Passaglia R de CAT, Haddad R, Eberlin MN, Laurindo FRM, Souza HP de, Corrêa FM de A, Oliveira AM de. Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia [Internet]. British Journal of Pharmacology. 2009 ; 157( 4): 568-580.[citado 2024 maio 31 ] Available from: https://doi.org/10.1111/j.1476-5381.2009.00165.x
Vancouver
Andrade CR de, Leite PF, Montezano AC, Casolari DA, Yogi A, Passaglia R de CAT, Haddad R, Eberlin MN, Laurindo FRM, Souza HP de, Corrêa FM de A, Oliveira AM de. Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia [Internet]. British Journal of Pharmacology. 2009 ; 157( 4): 568-580.[citado 2024 maio 31 ] Available from: https://doi.org/10.1111/j.1476-5381.2009.00165.x
Artigo de periodico
A comparative study of the antipyretic effects of indomethacin and dipyrone in rats (2002)
Souza, Glória Emília Petto; Cardoso, Rita Alessandra; Melo, Miriam Cristina Contim; Fabrício, Aline Sueli Coelho; Silva, Valéria Maria S.; Lora, M.; Brum-Fernandes, Artur José de; Rae, Giles A.; Ferreira, Sérgio Henrique; Zampronio, Aleksander Roberto
Source: Inflammation Research. Unidades: FCFRP, FM, FMRP
Assunto: FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Glória Emília Petto et al. A comparative study of the antipyretic effects of indomethacin and dipyrone in rats. Inflammation Research, v. 51, p. 24-32, 2002Tradução . . Disponível em: https://doi.org/10.1007/pl00000278. Acesso em: 31 maio 2024.
APA
Souza, G. E. P., Cardoso, R. A., Melo, M. C. C., Fabrício, A. S. C., Silva, V. M. S., Lora, M., et al. (2002). A comparative study of the antipyretic effects of indomethacin and dipyrone in rats. Inflammation Research, 51, 24-32. doi:10.1007/pl00000278
NLM
Souza GEP, Cardoso RA, Melo MCC, Fabrício ASC, Silva VMS, Lora M, Brum-Fernandes AJ de, Rae GA, Ferreira SH, Zampronio AR. A comparative study of the antipyretic effects of indomethacin and dipyrone in rats [Internet]. Inflammation Research. 2002 ; 51 24-32.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/pl00000278
Vancouver
Souza GEP, Cardoso RA, Melo MCC, Fabrício ASC, Silva VMS, Lora M, Brum-Fernandes AJ de, Rae GA, Ferreira SH, Zampronio AR. A comparative study of the antipyretic effects of indomethacin and dipyrone in rats [Internet]. Inflammation Research. 2002 ; 51 24-32.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/pl00000278

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Funding Agencies

Indexado em

Non normalized affiliation